Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | FAP | Q12884 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 2/20 | 0.38 |
| ▸ | REN | P00797 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5499080 | 0.90 | ACE (0.50) | ACEREN | |
| SCHEMBL4659800 | 0.88 | BCHE (0.38) | ACEREN | |
| SCHEMBL12253005 | 0.85 | DPP4 (0.40) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL20811437 | 0.83 | DPP4 (0.47) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL4956518 | 0.83 | POLB (0.41) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL4956515 | 0.83 | POLB (0.41) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL2207874 | 0.81 | NPSR1 (0.36) | ACEREN | |
| SCHEMBL6135698 | 0.81 | DPP7 (0.39) | DPP7 | |
| SCHEMBL6135700 | 0.81 | DPP7 (0.39) | DPP7 | |
| SCHEMBL2212354 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896452-B1 | N-FORMYL HYDROXYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2011-11-16 | — | — | EP | disclosed |
| US-8044199-B2 | N-formyl hydroxylamines compounds | VICURON HOLDINGS LLC (US) | 2011-10-25 | — | — | US | disclosed |
| US-20100063278-A1 | N-Formyl Hydroxylamines compounds | NOVARTIS AG (CH) | 2010-03-11 | — | — | US | disclosed |
| US-7615635-B2 | N-formyl hydroxylamines | NOVARTIS AG (CH) | 2009-11-10 | — | — | US | disclosed |
| US-7612059-B2 | Pyrrolidine bicyclic compounds and its derivatives, compositions and methods of use | VICURON PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090149509-A1 | NOVEL PYRROLIDINE BICYCLIC COMPOUNDS AND ITS DERIVATIVES, COMPOSITIONS AND METHODS OF USE | VICURON PHARMACEUTICALS INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20080161558-A1 | 1-[2-Cyclopentylmethyl-3-(formyl-hydroxy-amino)-propionyl]-pyrrolidine-2-carboxylic acid (5-fluoro-1-oxy-pyridin-2-yl)-amide; inhibitors of peptidyl deformylase (PDF), antimicrobials and antibiotics | VICURON HOLDINGS LLC | 2008-07-03 | — | — | US | disclosed |
| EP-1896452-A2 | N-FORMYL HYDROXYLAMINE COMPOUNDS | Novartis Pharma AG. (CH) | 2008-03-12 | — | — | EP | disclosed |
| EP-1406893-B1 | PYRROLIDINE BICYCLIC COMPOUNDS | VICURON PHARM INC (US) | 2007-04-18 | — | — | EP | disclosed |
| US-7148242-B2 | N-formyl hydroxylamine compounds, compositions and methods of use | NOVARTIS AG (CH) | 2006-12-12 | — | — | US | disclosed |
| WO-2006127576-A2 | N - FORMYL HYDROXYLAMINE COMPOUNDS AS PDF INHIBITORS | NOVARTIS AG (CH) | 2006-11-30 | — | — | WO | disclosed |
| US-6987104-B2 | Pyrrolidine bicyclic compounds and its derivatives, compositions and methods of use | VICURON PHARMACEUTICALS INC. (US) | 2006-01-17 | — | — | US | disclosed |
| US-20050277683-A1 | Novel pyrrolidine bicyclic compounds and its derivatives, compositions and methods of use | VICURON HOLDINGS LLC | 2005-12-15 | — | — | US | disclosed |
| EP-1406893-A1 | PYRROLIDINE BICYCLIC COMPOUNDS | Vicuron Pharmaceuticals, Inc. (US) | 2004-04-14 | — | — | EP | disclosed |
| EP-1401828-A1 | N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF | Vicuron Pharmaceuticals, Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030069223-A1 | Novel pyrrolidine bicyclic compounds and its derivatives, compositions and methods of use | VICURON HOLDINGS LLC | 2003-04-10 | — | — | US | disclosed |
| US-20030045479-A1 | Novel N-formyl hydroxylamine compounds, compositions and methods of use | VICURON HOLDINGS LLC | 2003-03-06 | — | — | US | disclosed |
| WO-2002102790-A1 | N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF | VICURON PHARMACEUTICALS INC. (US) | 2002-12-27 | — | — | WO | disclosed |
| WO-2002102791-A1 | PYRROLIDINE BICYCLIC COMPOUNDS | VICURON PHARMACEUTICALS INC. (US) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063278-A1 | N-Formyl Hydroxylamines compounds | PDF, MMP2, HNMT | DPP4 253/4885FAP 44/4885DPP8 341/4885 |
| US-20030069223-A1 | Novel pyrrolidine bicyclic compounds and its derivatives, compositions and methods of use | PDF, TPMT, NOD1 | DPP4 574/4885FAP 483/4885DPP8 588/4885 |
| US-20030045479-A1 | Novel N-formyl hydroxylamine compounds, compositions and methods of use | PDF, HNMT, AADAC | DPP4 830/4885FAP 49/4885DPP8 574/4885 |
| US-20050277683-A1 | Novel pyrrolidine bicyclic compounds and its derivatives, compositions and methods of use | PDF, PNPO, PDXK | DPP4 1211/4885FAP 1562/4885DPP8 1037/4885 |
| US-20090149509-A1 | NOVEL PYRROLIDINE BICYCLIC COMPOUNDS AND ITS DERIVATIVES, COMPOSITIONS AND METHODS OF USE | PDF, PNPO, PDXK | DPP4 1211/4885FAP 1562/4885DPP8 1037/4885 |
| US-20080161558-A1 | 1-[2-Cyclopentylmethyl-3-(formyl-hydroxy-amino)-propionyl]-pyrrolidine-2-carboxylic acid (5-fluoro-1-oxy-pyridin-2-yl)-amide; inhibitors of peptidyl deformylase (PDF), antimicrobials and antibiotics | PDF, MMP2, PEPD | DPP4 193/4885FAP 27/4885DPP8 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.